PMID- 23556114
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130405
LR  - 20240318
IS  - 2040-6207 (Print)
IS  - 2040-6215 (Electronic)
IS  - 2040-6207 (Linking)
VI  - 3
IP  - 2
DP  - 2012 Apr
TI  - Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support 
      in multiple myeloma.
PG  - 81-8
LID - 10.1177/2040620711433317 [doi]
AB  - OBJECTIVE: Induction high-dose chemotherapy followed by myeloablative melphalan 
      (HD-Mel) treatment and autologous hematopoietic stem-cell support (autoSCT) is a 
      standard treatment for multiple myeloma (MM) either upfront or in relapse after 
      conventional treatment. We performed a retrospective analysis of consecutive 
      patients undergoing a late repeat HD-Mel/autoSCT treatment for MM. METHODS: Data 
      from 24 consecutive patients with MM who underwent a myeloablative treatment with 
      HD-Mel late after completion of upfront first high-dose therapy were assessed for 
      toxicity, response, progression-free survival (PFS) and time to next treatment 
      (TTNT). These data were correlated with the results obtained after the initial 
      high dose therapy and autoSCT. RESULTS: A total of 23 patients were treated with 
      novel drugs (lenalidomide, thalidomide, bortezomib) after relapse to initial 
      autoSCT. The median overall survival (OS) of all patients was 90 months. 19 
      patients (79%) achieved a very good partial remission (VGPR) or complete 
      remission (CR) after initial autoSCT, compared with 42% after late autoSCT. PFS 
      and TTNT were 19 and 24 months after initial compared with 13 and 21 months after 
      late autoSCT. Univariate analysis identified initial response duration and the 
      achievement of a CR/VGPR after the initial transplantation to be associated with 
      prolonged response after repeat autoSCT. CONCLUSIONS: Our data indicate that late 
      high-dose treatment followed by autoSCT is safe and effective after upfront 
      intensive treatment, can bridge to allogeneic SCT, and encourage collection of an 
      additional graft.
FAU - Menzel, Helge
AU  - Menzel H
FAU - Hinmuller, Katarzyna
AU  - Hinmuller K
FAU - Kolb, Hans-Jochem
AU  - Kolb HJ
FAU - Schuster, Tibor
AU  - Schuster T
FAU - Hoellein, Alexander
AU  - Hoellein A
FAU - Peschel, Christian
AU  - Peschel C
FAU - Dechow, Tobias
AU  - Dechow T
FAU - Keller, Ulrich
AU  - Keller U
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ther Adv Hematol
JT  - Therapeutic advances in hematology
JID - 101549589
PMC - PMC3573432
OTO - NOTNLM
OT  - high-dose therapy
OT  - multiple myeloma
OT  - stem-cell transplantation
COIS- The authors declare no conflicts of interest.
EDAT- 2013/04/05 06:00
MHDA- 2013/04/05 06:01
PMCR- 2012/04/01
CRDT- 2013/04/05 06:00
PHST- 2013/04/05 06:00 [entrez]
PHST- 2013/04/05 06:00 [pubmed]
PHST- 2013/04/05 06:01 [medline]
PHST- 2012/04/01 00:00 [pmc-release]
AID - 10.1177_2040620711433317 [pii]
AID - 10.1177/2040620711433317 [doi]
PST - ppublish
SO  - Ther Adv Hematol. 2012 Apr;3(2):81-8. doi: 10.1177/2040620711433317.